Monday June 29, 03:40 PM Reuters

Aurobindo in court on S.Africa AIDS drug tender

JOHANNESBURG (Reuters) - Indian pharmaceutical company Aurobindo is taking South Africa's Treasury to court after it lost out to local drug firms in a $400 million contract for anti-retroviral AIDS drugs, the Treasury said.

A Treasury spokeswoman said Aurobindo had requested, via a South African, an explanation from the government on why it was overlooked for the contracts even though its tendered price for the drugs was on average cheaper than local products.

South African firm Aspen won 50 percent of the contract to supply South Africa's health system with life-prolonging ARV drugs last year and rival Adcock Ingram also won some of the business.

Treasury spokeswoman Thoraya Pandy said Aurobindo had asked for reasons on why it was overlooked.

"We submitted the reasons and the company will interrogate them through the courts, after which it can decide to pursue the case," said Pandy.

Other companies that were awarded the tender in June last year were GlaxoSmithKline, Medpro, Sonke and Merck Sharp and Dohme, a unit of Merck & Co.

Aurobindo could not immediately be reached for comment.

(For more news on Reuters Money click http://in.reuters.com/money)

RECENT BUSINESS NEWS

RELATED NEWS

RSS FEEDS

All headlines to your personalized My Yahoo! page
(Learn about My Yahoo! and RSS)
  • All Business News
  • India Business News
  • World Business News
  • Personal Finance News
More Finance RSS Feeds




Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for BSE and NSE(when not logged-in) See also delay times for other exchanges.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Prior to execution of any security trade, you are advised to consult your authorized financial advisor to verify the accuracy of all information. Neither Yahoo! nor any independent provider is liable for any informational errors, incompleteness or delays or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found herein.